Should we delay adjuvant breast radiotherapy for early stage breast cancers as the COVID-19 situation evolves?  

Would your practice vary based on hormone receptor or Her2 status?



Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at Henry Ford Health System
We have developed similar recommendations for our ...
Sign in or Register to read more

Answer from: Radiation Oncologist at Academic Institution

Answer from: Radiation Oncologist at Community Practice

Answer from: Radiation Oncologist at Community Practice